In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment of the CDMO market and the link between insufficient manufacturing capabilities across the industry and slow biosimilar approval rates.
Our ambition was to produce five or six biosimilar products. We are currently developing eight biosimilar products and have received approval for five, the largest number of biosimilar products approved by the FDA or EMA.
